<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NATEGLINIDE- nateglinide tablet </strong><br>Dr. Reddy's Laboratories Limited<br></p></div>
<h1><span class="Bold">Nateglinide Tablets USP</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Description"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Nateglinide tablets USP are oral antidiabetic agent used in the management of Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus [also known as non-insulin dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (<span class="product-label-link" type="condition" conceptid="201826" conceptname="Type 2 diabetes mellitus">NIDDM</span>) or adult-onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>]. Nateglinide, (-)-N-[(trans-4-isopropylcyclohexane)carbonyl]-D-phenylalanine, is structurally unrelated to the oral sulfonylurea insulin secretagogues.</p>
<p>The structural formula is as shown</p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7b28951-76d2-cabd-64a1-b74aa225c6e9&amp;name=structure.jpg"></p>
<p>Nateglinide is a white powder with a molecular weight of 317.43. It is freely soluble in methanol, ethanol, and chloroform, soluble in ether, sparingly soluble in acetonitrile and octanol, and practically insoluble in water. Nateglinide biconvex tablets contain 60 mg, or 120 mg, of nateglinide for oral administration.</p>
<p><span class="Bold">Inactive ingredients: </span>carnauba wax, copovidone, croscarmellose sodium, mannitol, silicon dioxide, sodium lauryl sulfate, sodium stearyl fumarate, corn starch and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL_PHARMACOLOGY"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="MechanismofAction"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">Mechanism of Action</span></h2>
<p class="First">Nateglinide is an amino-acid derivative that lowers blood glucose levels by stimulating insulin secretion from the pancreas. This action is dependent upon functioning beta-cells in the pancreatic islets. Nateglinide interacts with the ATP-sensitive potassium (K+<span class="Sub">ATP</span>) channel on pancreatic beta-cells. The subsequent depolarization of the beta cell opens the calcium channel, producing calcium influx and insulin secretion. The extent of insulin release is glucose dependent and diminishes at low glucose levels. Nateglinide is highly tissue selective with low affinity for heart and skeletal muscle.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Pharmacokinetics"></a><a name="section-2.2"></a><p></p>
<h2><span class="Bold">Pharmacokinetics</span></h2>
<p class="First">Absorption</p>
<p>Following oral administration immediately prior to a meal, nateglinide is rapidly absorbed with mean peak plasma drug concentrations (C<span class="Sub">max</span>) generally occurring within 1 hour (T<span class="Sub">max</span>) after dosing. When administered to patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> over the dosage range 60 mg to 240 mg three times a day for one week, nateglinide demonstrated linear pharmacokinetics for both AUC (area under the time/plasma concentration curve) and C<span class="Sub">max</span>. T<span class="Sub">max </span>was also found to be independent of dose in this patient population. Absolute bioavailability is estimated to be approximately 73%. When given with or after meals, the extent of nateglinide absorption (AUC) remains unaffected. However, there is a delay in the rate of absorption characterized by a decrease in C<span class="Sub">max</span> and a delay in time to peak plasma concentration (T<span class="Sub">max</span>). Plasma profiles are characterized by multiple plasma concentration peaks when nateglinide is administered under fasting conditions. This effect is diminished when nateglinide is taken prior to a meal.</p>
<p>Distribution</p>
<p>Based on data following intravenous (IV) administration of nateglinide, the steady-state volume of distribution of nateglinide is estimated to be approximately 10 liters in healthy subjects. Nateglinide is extensively bound (98%) to serum proteins, primarily serum albumin, and to a lesser extent α<span class="Sub">1 </span>acid glycoprotein. The extent of serum protein binding is independent of drug concentration over the test range of 0.1 to 10 mcg/mL.</p>
<p>Metabolism</p>
<p>Nateglinide is metabolized by the mixed-function oxidase system prior to elimination. The major routes of metabolism are hydroxylation followed by glucuronide conjugation. The major metabolites are less potent antidiabetic agents than nateglinide. The isoprene minor metabolite possesses potency similar to that of the parent compound nateglinide.</p>
<p><span class="Italics">In vitro</span> data demonstrate that nateglinide is predominantly metabolized by cytochrome P450 isoenzymes CYP2C9 (70%) and CYP3A4 (30%).</p>
<p>Excretion</p>
<p>Nateglinide and its metabolites are rapidly and completely eliminated following oral administration. Within 6 hours after dosing, approximately 75% of the administered <span class="Sup">14</span>C-nateglinide was recovered in the urine. Eighty-three percent of the <span class="Sup">14</span>C-nateglinide was excreted in the urine with an additional 10% eliminated in the feces. Approximately 16% of the <span class="Sup">14</span>C-nateglinide was excreted in the urine as parent compound. In all studies of healthy volunteers and patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, nateglinide plasma concentrations declined rapidly with an average elimination half-life of approximately 1.5 hours. Consistent with this short elimination half-life, there was no apparent accumulation of nateglinide upon multiple dosing of up to 240 mg three times daily for 7 days.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Druginteractions"></a><a name="section-2.3"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First"><span class="Italics">In vitro </span>drug metabolism studies indicate that nateglinide is predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%). Nateglinide is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the <span class="Italics">in vitro</span> metabolism of tolbutamide. Inhibition of CYP3A4 metabolic reactions was not detected in <span class="Italics">in vitro</span> experiments.</p>
<p>Glyburide:<span class="Bold"></span></p>
<p><span class="Bold"></span>In a randomized, multiple-dose crossover study, patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> were administered 120 mg nateglinide three times a day before meals for 1 day in combination with glyburide 10 mg daily. There were no clinically relevant alterations in the pharmacokinetics of either agent.</p>
<p>Metformin: </p>
<p>When nateglinide 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, there were no clinically relevant changes in the pharmacokinetics of either agent.</p>
<p>Digoxin:<span class="Bold"></span></p>
<p><span class="Bold"></span>When nateglinide 120 mg before meals was administered in combination with a single 1mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.</p>
<p>Warfarin:<span class="Bold"></span></p>
<p><span class="Bold"></span>When healthy subjects were administered nateglinide 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time was not affected.</p>
<p>Diclofenac:<span class="Bold"></span></p>
<p><span class="Bold"></span>Administration of morning and lunch doses of nateglinide 120 mg in combination with a single 75 mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SpecialPopulations"></a><a name="section-2.4"></a><p></p>
<h2><span class="Bold">Special Populations</span></h2>
<p class="First">Geriatric: </p>
<p>Age did not influence the pharmacokinetic properties of nateglinide. Therefore, no dose adjustments are necessary for elderly patients.</p>
<p>Gender: </p>
<p>No clinically significant differences in nateglinide pharmacokinetics were observed between men and women. Therefore, no dose adjustment based on gender is necessary.</p>
<p>Race: </p>
<p>Results of a population pharmacokinetic analysis including subjects of Caucasian, Black, and other ethnic origins suggest that race has little influence on the pharmacokinetics of nateglinide.</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </p>
<p>Compared to healthy matched subjects, patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and moderate-to-severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (CrCl 15 to 50 mL/min) not on dialysis displayed similar apparent clearance, AUC, and C<span class="Sub">max</span>. Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> on dialysis exhibited reduced overall drug exposure. However, hemodialysis patients also experienced reductions in plasma protein binding compared to the matched healthy volunteers.</p>
<p><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </p>
<p>The peak and total exposure of nateglinide in non-diabetic subjects with mild <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> were increased by 30% compared to matched healthy subjects. Nateglinide should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span>. (See <span class="Bold"><a href="#HepaticImpairment">PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>.</a></span>)</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Pharmacodynamics"></a><a name="section-2.5"></a><p></p>
<h2><span class="Bold">Pharmacodynamics</span></h2>
<p class="First">Nateglinide is rapidly absorbed and stimulates pancreatic insulin secretion within 20 minutes of oral administration. When nateglinide is dosed three times daily before meals there is a rapid rise in plasma insulin, with peak levels approximately 1 hour after dosing and a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> to baseline by 4 hours after dosing.</p>
<p>In a double-blind, controlled clinical trial in which nateglinide was administered before each of three meals, plasma glucose levels were determined over a 12-hour, daytime period after 7 weeks of treatment. Nateglinide was administered 10 minutes before meals. The meals were based on standard diabetic weight maintenance menus with the total caloric content based on each subject’s height. Nateglinide produced statistically significant decreases in fasting and postprandial glycemia compared to placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ClinicalStudies"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL STUDIES</span></h1>
<p class="First">A total of 3,566 patients were randomized in nine double-blind, placebo- or active-controlled studies 8 to 24 weeks in duration to evaluate the safety and efficacy of nateglinide. 3,513 patients had efficacy values beyond baseline. In these studies nateglinide was administered up to 30 minutes before each of three main meals daily.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Nateglinide"></a><a name="section-3.1"></a><p></p>
<h2><span class="Bold">Nateglinide Monotherapy Compared to Placebo</span></h2>
<p class="First">In a randomized, double-blind, placebo-controlled, 24-week study, patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with HbA<span class="Sub">1C</span> ≥ 6.8 % on diet alone were randomized to receive either nateglinide (60 mg or 120 mg three times daily before meals) or placebo. Baseline HbA<span class="Sub">1C</span> ranged from 7.9% to 8.1% and 77.8% of patients were previously untreated with oral antidiabetic therapy. Patients previously treated with antidiabetic medications were required to discontinue that medication for at least 2 months before randomization. The addition of nateglinide before meals resulted in statistically significant reductions in mean HbA<span class="Sub">1C</span> and mean fasting plasma glucose (FPG) compared to placebo (see <span class="Bold">Table 1</span>). The reductions in HbA<span class="Sub">1C</span> and FPG were similar for patients naïve to, and those previously exposed to, antidiabetic medications.</p>
<p>In this study, one episode of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (plasma glucose &lt;<span class="Bold"></span>36 mg/dL) was reported in a patient treated with nateglinide 120 mg three times daily before meals. No patients experienced <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> that required third party assistance. Patients treated with nateglinide had statistically significant mean increases in weight compared to placebo (see <span class="Bold">Table 1</span>).</p>
<p>In another randomized, double-blind, 24-week, active- and placebo-controlled study, patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> were randomized to receive nateglinide (120 mg three times daily before meals), metformin  500 mg (three times daily), a combination of nateglinide 120 mg (three times daily before meals) and metformin 500 mg (three times daily), or placebo. Baseline HbA<span class="Sub">1C</span> ranged from 8.3% to 8.4%. Fifty-seven percent of patients were previously untreated with oral antidiabetic therapy. Nateglinide monotherapy resulted in significant reductions in mean HbA<span class="Sub">1C</span> and mean FPG compared to placebo that were similar to the results of the study reported above (see <span class="Bold">Table 2</span>).</p>
<p><span class="Bold">Table 1: Endpoint results for a 24-week, fixed dose</span><span class="Bold">study of nateglinide<span class="Sup"></span> monotherapy</span></p>
<p><span class="Bold"> </span></p>
<table border="0" cellpadding="3" cellspacing="3" frame="below"><tbody class="Headless" align="center">
<tr class="First">
<td colspan="1" rowspan="1" valign="top"> </td>
<td valign="top"><span class="Bold">Placebo</span></td>
<td valign="top">
<span class="Bold">Nateglinide 60 mg </span><br><span class="Bold">three times daily </span><br><span class="Bold">before meals</span>
</td>
<td valign="top"><span class="Bold">Nateglinide 120 mg <br>three times daily <br>before meals</span></td>
</tr>
<tr align="center">
<td align="left"><span class="Bold">HbA<span class="Sub">1C</span> (%)</span></td>
<td valign="top">N=168</td>
<td valign="top">N=167</td>
<td valign="top">N=168</td>
</tr>
<tr>
<td align="left">Baseline (mean)</td>
<td valign="top">8</td>
<td valign="top">            7.9</td>
<td valign="top">8.1</td>
</tr>
<tr>
<td align="left">Change from baseline (mean)</td>
<td valign="top">+0.2</td>
<td valign="top">-0.3</td>
<td valign="top"> -0.5</td>
</tr>
<tr>
<td align="left">Difference from placebo (mean)    </td>
<td valign="top"> </td>
<td valign="top"> -0.5 <span class="Sup">a</span>
</td>
<td valign="top">   -0.7 <span class="Sup">a</span>
</td>
</tr>
<tr>
<td align="left" valign="bottom"><span class="Bold">FPG(mg/dL)</span></td>
<td valign="top">N=172</td>
<td valign="top">N=171</td>
<td valign="top">N=169</td>
</tr>
<tr>
<td align="left">Baseline (mean)</td>
<td valign="top">167.9</td>
<td valign="top"> 161</td>
<td valign="top"> 166.5</td>
</tr>
<tr>
<td align="left">Change from baseline (mean)</td>
<td valign="top">+9.1</td>
<td valign="top">+0.4</td>
<td valign="top">-4.5</td>
</tr>
<tr>
<td>Difference from placebo (mean)  </td>
<td valign="top"> </td>
<td valign="top">  -8.7 <span class="Sup">a</span>
</td>
<td valign="top">   -13.6 <span class="Sup">a</span> </td>
</tr>
<tr>
<td align="left"><span class="Bold">Weight (kg)</span></td>
<td valign="top">N=170</td>
<td valign="top">N=169</td>
<td valign="top">N=166</td>
</tr>
<tr>
<td align="left">Baseline (mean)</td>
<td valign="top">85.8</td>
<td valign="top">83.7</td>
<td valign="top">86.3</td>
</tr>
<tr>
<td align="left">Change from baseline (mean)</td>
<td valign="top">-0.7</td>
<td valign="top">+0.3</td>
<td valign="top">+0.9</td>
</tr>
<tr class="Last">
<td align="left">Difference from placebo (mean)</td>
<td valign="top"> </td>
<td valign="top">  +1 <span class="Sup">a</span>
</td>
<td valign="top">  +1.6 <span class="Sup">a</span>
</td>
</tr>
</tbody></table>
<p><span class="Sup">a</span> p-value ≤ 0.004<span class="Bold"></span></p>
<p><span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Monotherapy"></a><a name="section-3.2"></a><p></p>
<h2><span class="Bold">Nateglinide Monotherapy Compared to Other Oral Antidiabetic Agents</span></h2>
<p class="First">Glyburide</p>
<p>In a 24-week, double-blind, active-controlled trial, patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who had been on a sulfonylurea for ≥ 3 months and who had a baseline HbA<span class="Sub">1C</span> ≥ 6.5 % were randomized to receive nateglinide (60 mg or 120 mg three times daily before meals) or glyburide 10 mg once daily. Patients randomized to nateglinide had significant increases in mean HbA<span class="Sub">1C</span> and mean FPG at endpoint compared to patients randomized to glyburide.</p>
<p>Metformin</p>
<p>In another randomized, double-blind, 24-week, active- and placebo-controlled study, patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> were randomized to receive nateglinide (120 mg three times daily before meals), metformin 500 mg (three times daily), a combination of nateglinide 120 mg (three times daily before meals) and metformin 500 mg (three times daily), or placebo. Baseline HbA<span class="Sub">1C </span>ranged from 8.3% to 8.4%. Fifty-seven percent of patients were previously untreated with oral antidiabetic therapy. Patients previously treated with antidiabetic medications were required to discontinue medication for at least 2 months before randomization.The reductions in mean HbA<span class="Sub">1C</span> and mean FPG at endpoint with metformin monotherapy were significantly greater than the reductions in these variables with nateglinide monotherapy (see <span class="Bold">Table 2</span>). Relative to placebo, nateglinide monotherapy was associated with significant increases in mean weight whereas metformin monotherapy was associated with significant decreases in mean weight. Among the subset of patients naïve to antidiabetic therapy, the reductions in mean HbA<span class="Sub">1C</span> and mean FPG for nateglinide monotherapy were similar to those for metformin monotherapy (see <span class="Bold">Table 2</span>). Among the subset of patients previously treated with other antidiabetic agents, primarily glyburide, HbA<span class="Sub">1C</span> in the nateglinide monotherapy group increased slightly from baseline, whereas HbA<span class="Sub">1C</span> was reduced in the metformin monotherapy group (see <span class="Bold">Table 2</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CombinationTherapy"></a><a name="section-3.3"></a><p></p>
<h2><span class="Bold">Nateglinide Combination Therapy</span></h2>
<p class="First">Metformin</p>
<p>In the active and placebo-controlled study of metformin and nateglinide described above, the combination of nateglinide and metformin resulted in statistically significantly greater reductions in HbA<span class="Sub">1C</span> and FPG compared to either nateglinide or metformin monotherapy (see <span class="Bold">Table</span><span class="Bold">2</span>). Nateglinide, alone or in combination with metformin, significantly reduced the prandial glucose elevation from pre­-meal to 2-hours post-meal compared to placebo and metformin alone.</p>
<p>In this study, one episode of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (plasma glucose ≤ 36 mg/dL) was reported in a patient receiving the combination of nateglinide and metformin and four episodes of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were reported in a single patient in the metformin treatment arm. No patient experienced an episode of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> that required third party assistance. Compared to placebo, nateglinide monotherapy was associated with a statistically significant increase in weight, while no significant change in weight was observed with combined nateglinide and metformin therapy (see <span class="Bold">Table</span><span class="Bold">2</span>).</p>
<p>In another 24-week, double-blind, placebo-controlled trial, patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with HbA<span class="Sub">1C</span> ≥ 6.8% after treatment with metformin (≥ 1500 mg daily for ≥ 1 month) were first entered into a four week run-in period of metformin monotherapy (2000 mg daily) and then randomized to receive nateglinide (60 mg or 120 mg three times daily before meals) or placebo in addition to metformin. Combination therapy with nateglinide and metformin was associated with statistically significantly greater reductions in HbA<span class="Sub">1C</span> compared to metformin monotherapy (-0.4% and -0.6% for nateglinide 60 mg and nateglinide 120 mg plus metformin, respectively).</p>
<p><span class="Bold">Table 2: End point results for a 24-week study of nateglinide monotherapy and combination with metformin</span></p>
<p></p>
<table border="0" cellpadding="3" cellspacing="3" width="97%"><tbody class="Headless" align="left">
<tr class="First">
<td colspan="1" rowspan="1" valign="top"> </td>
<td valign="top"><span class="Bold">Placebo</span></td>
<td valign="top">
<span class="Bold">Nateglinide 120 mg </span><br><span class="Bold">three times daily </span><br><span class="Bold">before meals</span>
</td>
<td valign="top">
<span class="Bold">Metformin </span><span class="Bold">500 mg</span><br><span class="Bold"> three times daily</span>
</td>
<td valign="top">
<span class="Bold">Nateglinide<span class="Sup">  </span>120 mg </span><br><span class="Bold">before meals </span><br><span class="Bold">plus Metformin*</span>
</td>
</tr>
<tr align="left">
<td valign="top">
<span class="Bold">HbA<span class="Sub">1C</span> (%)</span><span class="Bold">All</span>
</td>
<td valign="top"> N=160<span class="Bold"></span>
</td>
<td valign="top">  N=171<span class="Bold"></span>
</td>
<td valign="top"> N=172<span class="Bold"></span>
</td>
<td valign="top"> N=162<span class="Bold"></span>
</td>
</tr>
<tr align="left">
<td valign="top">Baseline (mean)</td>
<td valign="top">8.3</td>
<td valign="top">8.3</td>
<td valign="top">8.4</td>
<td valign="top">8.4</td>
</tr>
<tr align="left">
<td valign="top">Change from baseline (mean)</td>
<td valign="top">+0.4</td>
<td valign="top">-0.4<span class="Sup">bc</span>
</td>
<td valign="top">-0.8<span class="Sup">c</span>
</td>
<td valign="top">-1.5</td>
</tr>
<tr align="left">
<td valign="top">Difference from placebo </td>
<td valign="top"> </td>
<td valign="top">-0.8<span class="Sup">a</span>
</td>
<td valign="top">-1.2<span class="Sup">a</span>
</td>
<td valign="top">-1.9<span class="Sup">a</span>
</td>
</tr>
<tr align="left">
<td valign="top"><span class="Bold">Naïve</span></td>
<td valign="top">N=98</td>
<td valign="top">N=99</td>
<td valign="top">N=98</td>
<td valign="top">N=81</td>
</tr>
<tr align="left">
<td valign="top">Baseline (mean)</td>
<td valign="top">8.2</td>
<td valign="top">8.1</td>
<td valign="top">8.3</td>
<td valign="top">8.2</td>
</tr>
<tr align="left">
<td valign="top">Change from baseline (mean)</td>
<td valign="top">+0.3</td>
<td valign="top">-0.7 <span class="Sup">c</span>
</td>
<td valign="top">-0.8 <span class="Sup">c</span>
</td>
<td valign="top">-1.6</td>
</tr>
<tr align="left">
<td valign="top">Difference from placebo</td>
<td valign="top"> </td>
<td valign="top">-1 <span class="Sup">a</span>
</td>
<td valign="top">-1.1 <span class="Sup">a</span>
</td>
<td valign="top">  -1.9 <span class="Sup">a</span> </td>
</tr>
<tr align="left">
<td valign="top"><span class="Bold">Non-Naïve</span></td>
<td valign="top">N=62</td>
<td valign="top">N=72</td>
<td valign="top">N=74</td>
<td valign="top">N=81</td>
</tr>
<tr align="left">
<td valign="top">Baseline (mean)<span class="Bold"></span>
</td>
<td valign="top">8.3</td>
<td valign="top">8.5</td>
<td valign="top">8.7</td>
<td valign="top">8.7</td>
</tr>
<tr align="left">
<td valign="top">Change from baseline (mean)<span class="Bold"></span>
</td>
<td valign="top">+0.6</td>
<td colspan="1" rowspan="1" valign="top"> +0.004 <span class="Sup">bc</span>
</td>
<td valign="top">-0.8 <span class="Sup">c</span>
</td>
<td valign="top">-1.4</td>
</tr>
<tr align="left">
<td valign="top">Difference from placebo<span class="Bold"></span>
</td>
<td valign="top"> </td>
<td valign="top">-0.6<span class="Sup"> a</span>
</td>
<td valign="top">-1.4 <span class="Sup">a</span>
</td>
<td valign="top"> -2 <span class="Sup">a</span>
</td>
</tr>
<tr align="left">
<td valign="top"><span class="Bold">FPG (mg/dL)</span></td>
<td valign="top"> </td>
<td valign="top"> </td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr align="left">
<td valign="top"><span class="Bold">All</span></td>
<td valign="top">N=166</td>
<td valign="top">N=173</td>
<td valign="top">N=174</td>
<td valign="top">N=167</td>
</tr>
<tr align="left">
<td valign="top">Baseline (mean)<span class="Bold"></span>
</td>
<td valign="top">194</td>
<td valign="top">196.5</td>
<td valign="top">196</td>
<td valign="top">197.7</td>
</tr>
<tr align="left">
<td valign="top">Change from baseline (mean)</td>
<td valign="top">  +8</td>
<td colspan="1" rowspan="1" valign="top">-13.1 <span class="Sup">bc</span>
</td>
<td valign="top">-30 <span class="Sup">c</span>
</td>
<td valign="top">-44.9</td>
</tr>
<tr align="left">
<td valign="top">Difference from placebo</td>
<td valign="top"> </td>
<td colspan="1" rowspan="1" valign="top"> -21.1 <span class="Sup">a</span>
</td>
<td valign="top">-38 <span class="Sup">a</span>
</td>
<td valign="top">-52.9 <span class="Sup">a</span>
</td>
</tr>
<tr align="left">
<td valign="top">
<span class="Bold">Weight (kg)</span><span class="Bold">All</span>
</td>
<td valign="top"> N=160</td>
<td valign="top"> N=169</td>
<td valign="top"> N=169</td>
<td valign="top"> N=160</td>
</tr>
<tr align="left">
<td valign="top">Baseline (mean)<span class="Bold"></span>
</td>
<td valign="top">85</td>
<td valign="top">85</td>
<td valign="top">86</td>
<td valign="top"> 87.4</td>
</tr>
<tr align="left">
<td valign="top">Change from baseline (mean)</td>
<td valign="top">-0.4</td>
<td colspan="1" rowspan="1" valign="top">+0.9 <span class="Sup">bc</span>
</td>
<td valign="top">-0.1</td>
<td valign="top">+0.2</td>
</tr>
<tr class="Last" align="left">
<td valign="top">Difference from placebo</td>
<td valign="top"> </td>
<td colspan="1" rowspan="1" valign="top">+1.3 <span class="Sup">a</span>
</td>
<td valign="top">+0.3</td>
<td valign="top">+0.6</td>
</tr>
</tbody></table>
<p><span class="Bold"></span></p>
<p><span class="Sup">a</span> p-value ≤ 0.05 vs. placebo</p>
<p><span class="Sup">b</span> p-value ≤ 0.03 vs. metformin</p>
<p><span class="Sup">c</span> p-value ≤ 0.05 vs. combination</p>
<p>*Metformin was administered three times daily</p>
<p></p>
<p>Rosiglitazone</p>
<p>A 24-week, double blind multicenter, placebo-controlled trial was performed in patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> not adequately controlled after a therapeutic response to rosiglitazone monotherapy  8 mg daily. The addition of nateglinide (120 mg three times per day with meals) was associated with statistically significantly greater reductions in HbA<span class="Sub">1C</span> compared to rosiglitazone monotherapy. The difference was -0.77% at 24 weeks. The mean change in weight from baseline was about +3 kg for patients treated with nateglinide plus rosiglitazone vs about +1 kg for patients treated with placebo plus rosiglitazone.</p>
<p>Glyburide</p>
<p>In a 12-week study of patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on glyburide 10 mg once daily, the addition of nateglinide (60 mg or 120 mg three times daily before meals) did not produce any additional benefit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Indications_and_Usage"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Nateglinide tablets are contraindicated in patients with: </p>
<p>1. Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or its inactive ingredients. </p>
<p>2. Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </p>
<p>3. <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span>. This condition should be treated with insulin.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Macrovascular"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">Macrovascular Outcomes: </span></h2>
<p class="First">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with nateglinide or any other antidiabetic drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Hyproglycemia"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>:</span></h2>
<p class="First">All oral blood glucose lowering drugs that are absorbed systemically are capable of producing <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. The frequency of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> is related to the severity of the <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the level of glycemic control, and other patient characteristics. Geriatric patients, malnourished patients, and those with adrenal or <span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">pituitary insufficiency</span> or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are more susceptible to the glucose lowering effect of these treatments. The risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be increased by strenuous physical exercise, ingestion of alcohol, insufficient caloric intake on an acute or chronic basis, or combinations with other oral antidiabetic agents. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> may be difficult to recognize in patients with <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">autonomic neuropathy</span> and/or those who use beta-blockers. Nateglinide should be administered prior to meals to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Patients who skip meals should also skip their scheduled dose of nateglinide to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="HepaticImpairment"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span></h2>
<p class="First">Nateglinide should be used with caution in patients with moderate-to-severe liver disease because such patients have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LossofGlycemicControl"></a><a name="section-6.4"></a><p></p>
<h2><span class="Bold">Loss of Glycemic Control</span></h2>
<p class="First">Transient loss of glycemic control may occur with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or surgery. Insulin therapy may be needed instead of nateglinide therapy at such times. Secondary failure, or reduced effectiveness of nateglinide over a period of time, may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="InformationforPatients"></a><a name="section-6.5"></a><p></p>
<h2><span class="Bold">Information for Patients</span></h2>
<p class="First">Patients should be informed of the potential risks and benefits of nateglinide and of alternative modes of therapy. The risks and management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> should be explained. Patients should be instructed to take nateglinide 1 to 30 minutes before ingesting a meal, but to skip their scheduled dose if they skip the meal so that the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> will be reduced. Drug interactions should be discussed with patients. Patients should be informed of potential drug-­drug interactions with nateglinide.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LaboratoryTests"></a><a name="section-6.6"></a><p></p>
<h2><span class="Bold">Laboratory Tests</span></h2>
<p class="First">Response to therapies should be periodically assessed with glucose values and HbA<span class="Sub">1C</span> levels</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DI"></a><a name="section-6.7"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<p class="First">Nateglinide is highly bound to plasma proteins (98%), mainly albumin. <span class="Italics">In vitro</span> displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding. Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide <span class="Italics">in vitro</span>. However, prudent evaluation of individual cases is warranted in the clinical setting.</p>
<p>Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, guanethidine, and CYP2C9 inhibitors (e.g. fluconazole, amiodarone, miconazole, oxandrolone) may potentiate the hypoglycemic action of nateglinide and other oral antidiabetic drugs.</p>
<p>Certain drugs including thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, rifampin, phenytoin and dietary supplements (St John’s wort) may reduce the hypoglycemic action of nateglinide and other oral antidiabetic drugs. Somatostatin analogues may potentiate or attenuate the hypoglycemic action of nateglinide.</p>
<p>When these drugs are administered to or withdrawn from patients receiving nateglinide, the patient should be observed closely for changes in glycemic control.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Drug_FoodInteractions"></a><a name="section-6.8"></a><p></p>
<h2><span class="Bold">Drug/Food Interactions</span></h2>
<p class="First">The pharmacokinetics of nateglinide were not affected by the composition of a meal (high protein, fat, or carbohydrate). However, peak plasma levels were significantly reduced when nateglinide was administered 10 minutes prior to a liquid meal. Nateglinide did not have any effect on gastric emptying in healthy subjects as assessed by acetaminophen testing.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="C_M_IF"></a><a name="section-6.9"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">Carcinogenicity:</p>
<p><span class="Bold"></span>A two-year carcinogenicity study in Sprague-Dawley rats was performed with oral doses of nateglinide up to 900 mg/kg/day, which produced AUC exposures in male and female rats approximately 30 and 40 times the human therapeutic exposure respectively with a recommended nateglinide dose of 120 mg, three times daily before meals. A two-year carcinogenicity study in B6C3F1 mice was performed with oral doses of nateglinide up to 400 mg/kg/day, which produced AUC exposures in male and female mice approximately 10 and 30 times the human therapeutic exposure with a recommended nateglinide dose of 120 mg, three times daily before meals. No evidence of a tumorigenic response was found in either rats or mice.</p>
<p>Mutagenesis:<span class="Bold"></span></p>
<p><span class="Bold"></span>Nateglinide was not genotoxic in the <span class="Italics">in vitro</span> Ames test, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, chromosome aberration assay in Chinese hamster lung cells, or in the <span class="Italics">in vivo</span> mouse micronucleus test.</p>
<p>Impairment of Fertility: </p>
<p>Fertility was unaffected by administration of nateglinide to rats at doses up to 600 mg/kg (approximately16 times the human therapeutic exposure with a recommended nateglinide dose of 120 mg three times daily before meals).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Pregnancy"></a><a name="section-6.10"></a><p></p>
<h2><span class="Bold">Pregnancy</span></h2>
<p class="First">Pregnancy Category C</p>
<p>Nateglinide was not teratogenic in rats at doses up to 1000 mg/kg (approximately 60 times the human therapeutic exposure with a recommended nateglinide dose of 120 mg, three times daily before meals). In the rabbit, embryonic development was adversely affected and the incidence of gallbladder agenesis or small gallbladder was increased at a dose of 500 mg/kg (approximately 40 times the human therapeutic exposure with a recommended nateglinide dose of 120 mg, three times daily before meals). There are no adequate and well-controlled studies in pregnant women. Nateglinide should not be used during pregnancy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LaborandDelivery"></a><a name="section-6.11"></a><p></p>
<h2><span class="Bold">Labor and Delivery</span></h2>
<p class="First">The effect of nateglinide on labor and delivery in humans is not known.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="NursingMothers"></a><a name="section-6.12"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">Studies in lactating rats showed that nateglinide is excreted in the milk; the AUC<span class="Sub">0-48h</span> ratio in milk to plasma was approximately 1:4. During the peri- and postnatal period body weights were lower in offspring of rats administered nateglinide at 1000 mg/kg (approximately 60 times the human therapeutic exposure with a recommended nateglinide dose of 120 mg, three times daily before meals). It is not known whether nateglinide is excreted in human milk. Because many drugs are excreted in human milk, nateglinide should not be administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="PediatricUSe"></a><a name="section-6.13"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">Clinical trials to demonstrate the safety and effectiveness in pediatric patients have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="GeriatricUse"></a><a name="section-6.14"></a><p></p>
<h2><span class="Bold">Geriatric Use</span></h2>
<p class="First">No differences were observed in safety or efficacy of nateglinide between patients age 65 and over, and those under age 65. However, greater sensitivity of some older individuals to nateglinide therapy cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AdverseReactions"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In clinical trials, approximately 2,600 patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> were treated with nateglinide. Of these, approximately 1,335 patients were treated for 6 months or longer and approximately 190 patients for one year or longer.</p>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was relatively uncommon in all treatment arms of the clinical trials. Only 0.3% of nateglinide patients discontinued due to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.Symptoms suggestive of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> have been observed after administration of nateglinide. These symptoms included <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">trembling</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span>, especially <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, were no more common in patients using the combination of nateglinide and metformin than in patients receiving metformin alone. Likewise, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> was no more common in patients using the combination of nateglinide and rosiglitazone than in patients receiving rosiglitazone alone. The following table lists events that occurred more frequently in nateglinide patients than placebo patients in controlled clinical trials.</p>
<p><span class="Bold">Common Adverse Events (</span><span class="Bold">≥ 2% in nateglinide patients) in Nateglinide<span class="Sup"></span>Monotherapy Trials (% of patients</span><span class="Bold">)</span></p>
<table border="0" cellpadding="5" cellspacing="1"><tbody class="Headless">
<tr class="First">
<td valign="top"><span class="Bold"> </span></td>
<td valign="top">
<span class="Bold">Placebo </span><br>N=458</td>
<td valign="top">
<span class="Bold">Nateglinide</span><br>N=1441</td>
</tr>
<tr>
<td valign="top"><span class="Bold Underline">Preferred Term</span></td>
<td valign="top"> </td>
<td valign="top"> </td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Infection</span></td>
<td valign="top">8.1</td>
<td valign="top">10.5</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td valign="top">3.7</td>
<td valign="top">4.0</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Symptoms</span></td>
<td valign="top">2.6</td>
<td valign="top">3.6</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td valign="top">2.2</td>
<td valign="top">3.6</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthropathy</span></td>
<td valign="top">2.2</td>
<td valign="top">3.3</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td valign="top">3.1</td>
<td valign="top">3.2</td>
</tr>
<tr>
<td valign="top">Accidental <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Trauma</span></td>
<td valign="top">1.7</td>
<td valign="top">2.9</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td valign="top">2.6</td>
<td valign="top">2.7</td>
</tr>
<tr>
<td valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td valign="top">2.2</td>
<td valign="top">2.4</td>
</tr>
<tr class="Last">
<td valign="top"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></td>
<td valign="top">0.4</td>
<td valign="top">2.4</td>
</tr>
</tbody></table>
<p> </p>
<p>During post-marketing experience, rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been reported. Similarly, cases of <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span> and elevated liver enzymes have been reported.<span class="Bold"></span></p>
<p><span class="Bold"></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LaboratoryAbnormalities"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">Laboratory Abnormalities</span></h2>
<p class="First">Uric Acid: </p>
<p>There were increases in mean uric acid levels for patients treated with nateglinide alone, nateglinide in combination with metformin, metformin alone, and glyburide alone. The respective differences from placebo were 0.29 mg/dL, 0.45 mg/dL, 0.28 mg/dL, and 0.19 mg/dL. The clinical significance of these findings is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Overdosage"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In a clinical study in patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, nateglinide was administered in increasing doses up to 720 mg a day for 7 days and there were no clinically significant adverse events reported. There have been no instances of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with nateglinide in clinical trials. However, an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may result in an exaggerated glucose-lowering effect with the development of hypoglycemic symptoms. Hypoglycemic symptoms without <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> or neurological findings should be treated with oral glucose and adjustments in dosage and/or meal patterns. Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reactions</span> with <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, or other neurological symptoms should be treated with intravenous glucose. As nateglinide is highly protein bound, dialysis is not an efficient means of removing it from the blood.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DosageandAdministration"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Nateglinide tablets should be taken 1 to 30 minutes prior to meals.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="MonotherapyandCombination"></a><a name="section-9.1"></a><p></p>
<h2><span class="Bold">Monotherapy and Combination with Metformin or a Thiazolidinedione</span></h2>
<p class="First">The recommended starting and maintenance dose of nateglinide tablets, alone or in combination with metformin or a thiazolidinedione, is 120 mg three times daily before meals.</p>
<p>The 60 mg dose of nateglinide tablets, either alone or in combination with metformin or a thiazolidinedione, may be used in patients who are near goal HbA<span class="Sub">1C</span> when treatment is initiated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DosageinGeriatricPatients"></a><a name="section-9.2"></a><p></p>
<h2><span class="Bold">Dosage in Geriatric Patients</span></h2>
<p class="First">No special dose adjustments are usually necessary. However, greater sensitivity of some individuals to nateglinide tablets therapy cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="DosageinRenalandHepaticImpairment"></a><a name="section-9.3"></a><p></p>
<h2><span class="Bold">Dosage in Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h2>
<p class="First">No dosage adjustment is necessary in patients with mild-to-severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or in patients with mild <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. Dosing of patients with moderate-to-severe hepatic dysfunction has not been studied. Therefore, nateglinide tablets should be used with caution in patients with moderate-to-severe liver disease (see<span class="Bold"></span><span class="Bold"><a href="#HepaticImpairment">PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>)</a></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="HowSupplied"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Nateglinide tablets USP are available as 60 mg white to off-white, round, biconvex tablets embossed with ‘RDY’ on one side and ‘328’ on other side and they are supplied in bottles of 30, 90, 100, 500 and unit dose package of 100 (10 x 10).</p>
<p>Bottles of 30                                                               NDC 55111-328-30</p>
<p>Bottles of 90                                                               NDC 55111-328-90</p>
<p>Bottles of 100                                                             NDC 55111-328-01</p>
<p>Bottles of 500                                                             NDC 55111-328-05</p>
<p>Unit dose package of 100 (10 x 10)                           NDC 55111-328-78</p>
<p>Nateglinide tablets USP are available as 120 mg white to off-white, round, biconvex tablets embossed with ‘RDY’ on one side and ‘329’ on other side and they are supplied in bottles of 30, 90, 100, 500 and unit dose package of 100 (10 x 10).</p>
<p>Bottles of 30                                                               NDC 55111-329-30</p>
<p>Bottles of 90                                                               NDC 55111-329-90</p>
<p>Bottles of 100                                                             NDC 55111-329-01</p>
<p>Bottles of 500                                                              NDC 55111-329-05</p>
<p>Unit dose package of 100 (10 x 10)                           NDC 55111-329-78</p>
<p><span class="Bold">Storage</span></p>
<p><span class="Bold"></span>Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight container, USP.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ManufacturerAddress"></a><a name="section-11"></a><p></p>
<h1></h1>
<p class="First">R<span class="Sub">X</span> Only </p>
<p>Manufactured by:</p>
<p><span class="Bold">Dr. Reddy’s Laboratories Limited</span></p>
<p> Bachupally – 500 090 INDIA </p>
<p>Revised:0415</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_6ddc6aab-af4e-e7a4-0e64-54032e970b7b"></a><a name="section-12"></a><p></p>
<h1>Package Label. Principal Display Panel</h1>
<p class="First">Nateglinide Tablets, 60 mg Container Label</p>
<p><img alt="container1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7b28951-76d2-cabd-64a1-b74aa225c6e9&amp;name=container1.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_64ccd5e1-1f65-b648-0463-f26d934c4c81"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First">Nateglinide Tablets, 60 mg Carton Label</p>
<p><img alt="carton1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7b28951-76d2-cabd-64a1-b74aa225c6e9&amp;name=carton1.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_4fdca39a-cc36-55be-9989-72512d500e80"></a><a name="section-14"></a><p></p>
<h1></h1>
<p class="First">Nateglinide Tablets, 120 mg Container label</p>
<p><img alt="container2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7b28951-76d2-cabd-64a1-b74aa225c6e9&amp;name=container2.jpg"></p>
<p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_ff5f08ab-ba2d-3b87-81f6-1a768fdfcf39"></a><a name="section-15"></a><p></p>
<h1></h1>
<p class="First">Nateglinide Tablets, 120 mg Carton Label</p>
<p><img alt="carton2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f7b28951-76d2-cabd-64a1-b74aa225c6e9&amp;name=carton2.jpg"></p>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NATEGLINIDE 		
					</strong><br><span class="contentTableReg">nateglinide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55111-328</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>nateglinide</strong> (nateglinide) </td>
<td class="formItem">nateglinide</td>
<td class="formItem">60 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carnauba wax</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>copovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium stearyl fumarate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RDY;328</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55111-328-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55111-328-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:55111-328-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:55111-328-05</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:55111-328-78</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:55111-328-79</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077461</td>
<td class="formItem">09/09/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NATEGLINIDE 		
					</strong><br><span class="contentTableReg">nateglinide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55111-329</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>nateglinide</strong> (nateglinide) </td>
<td class="formItem">nateglinide</td>
<td class="formItem">120 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carnauba wax</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>copovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium stearyl fumarate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RDY;329</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55111-329-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55111-329-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:55111-329-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:55111-329-05</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:55111-329-78</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:55111-329-79</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077461</td>
<td class="formItem">09/09/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Dr. Reddy's Laboratories Limited
							(650562841)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Dr. Reddy's Laboratories Limited (FTOIII)</td>
<td class="formItem"></td>
<td class="formItem">918608162</td>
<td class="formItem">analysis(55111-328, 55111-329), manufacture(55111-328, 55111-329)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7a130a11-a0a6-b96d-6862-850a291401fd</div>
<div>Set id: f7b28951-76d2-cabd-64a1-b74aa225c6e9</div>
<div>Version: 5</div>
<div>Effective Time: 20150420</div>
</div>
</div> <div class="DistributorName">Dr. Reddy's Laboratories Limited</div></p>
</body></html>
